Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Synchrony Financial (SYF) Price & Performance

Heron Therapeutics IncTrade
Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Synchrony Financial — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Synchrony Financial trades at $73 (market cap $24.69B). The key difference: Synchrony Financial is far larger — about 270× Heron Therapeutics Inc's market cap, and Synchrony Financial pays a 1.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXSYF
Market Cap
$91.46M$24.69B
Sector
HealthFinancials
52-Week High
$1.96$88.47
52-Week Low
$0.39$63.78
Enterprise Value
$189.36M
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Synchrony Financial

Synchrony Financial (SYF) trades at $73.41, down 0.29% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 7.62, net income margin of 24.06%, and consistent earnings beats. Recent corporate actions include a $0.30 dividend payment in May 2026. Cash flow remains positive despite projected 2026 challenges. Technical indicators show mixed signals with RSI at neutral levels but bearish moving averages.

SYF presents value opportunity with attractive valuation metrics and strong profitability, though facing near-term technical headwinds. Key risks include economic sensitivity as a consumer lender and potential margin pressure from rising rates. Analyst consensus remains bullish with $86.38 price target representing 17.7% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF